EVALUATION OF BRONCHIOLITIS MANAGEMENT PRACTICES AGAINST NICE GUIDELINES (NG9): A BASELINE CLINICAL AUDIT
Main Article Content
Keywords
Bronchiolitis, clinical audit, NICE guidelines, quality improvement, unnecessary medications, Pakistan
Abstract
Background
Bronchiolitis is the leading cause of hospitalization in infants under two years. International guidelines, including NICE NG9, recommend supportive care only and explicitly discourage routine bronchodilators, corticosteroids, and antibiotics. Despite this, off-guideline prescribing remains common in low- and middle-income countries. We conducted this audit to evaluate compliance with NICE NG9 in a tertiary care hospital in Pakistan.
METHODS
A retrospective, criterion-based baseline clinical audit was performed at Paediatric B Ward, Saidu Group of Teaching Hospital, Swat. Fifty consecutive patients aged <24 months with a discharge diagnosis of bronchiolitis (January – March 2026) were included. Data were extracted from medical records using a standardized proforma. Five standards from NICE NG9 were assessed: (1) diagnosis documentation, (2) hydration assessment and management, (3) oxygen therapy for SpO₂ <92%, (4) appropriate NG intubation, and (5) avoidance of unnecessary medications (bronchodilators, corticosteroids, antibiotics without bacterial infection). Target compliance was ≥90% for supportive standards and <10% for unnecessary medication use.
Results
Complete compliance was achieved for diagnosis documentation (50/50, 100%), oxygen therapy (12/12, 100%), and NG intubation (3/3, 100%). Hydration assessment and management compliance was 96% (48/50). However, 38/50 (76%) patients received at least one unnecessary medication, far exceeding the <10% target. Bronchodilators were prescribed to 30 (60%), antibiotics without bacterial evidence to 24 (48%), and corticosteroids to 20 (40%). Eighteen patients (36%) received two or more unnecessary drug classes.
ConclusionsSupportive care for bronchiolitis was excellent. However, unnecessary pharmacological treatment is highly prevalent (76%). This represents a major quality gap requiring urgent intervention. We propose a low-cost bundle including a ward protocol, visual aids, monthly prescription review, and antibiotic stewardship, with a re-audit at 3 months to target <20% unnecessary medication use.
References
2. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years, 2000–2015: a systematic analysis. Lancet. 2017;390(10098):946-58.
3. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545-55.
4. Kirolos A, Manti S, Blacow R, et al. A systematic review of clinical practice guidelines for the diagnosis and management of bronchiolitis. J Infect Dis. 2020;222(Suppl 7):S672-S679.
5. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2014;2014(6):CD001266.
6. Brusco NK, Chacko A, Wilson D, et al. Epinephrine for bronchiolitis: systematic review and meta-analysis. Pediatrics. 2021;147(3):e2020005028.
7. Fernandes RM, Bialy LM, Vandermeer B, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2013;2013(6):CD004878.
8. Farley R, Spurling GK, Eriksson L, et al. Antibiotics for bronchiolitis in children under two years of age. Cochrane Database Syst Rev. 2014;2014(10):CD005189.
9. Duttweiler L, Nadal D, Frey B. Pulmonary and systemic bacterial co-infections in severe RSV bronchiolitis. Arch Dis Child. 2004;89(12):1155-7.
10. National Institute for Health and Care Excellence. Bronchiolitis in children: diagnosis and management. NICE guideline NG9. London: NICE; 2021 (updated May 2021).
11. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474-502.
12. Scottish Intercollegiate Guidelines Network. Bronchiolitis in children. SIGN guideline 160. Edinburgh: SIGN; 2019.
13. Royal College of Paediatrics and Child Health. National Bronchiolitis Audit 2022 Annual Report. London: RCPCH; 2022.
14. Flores G, Lin H, Walker C, et al. Unnecessary care for bronchiolitis decreases with hospital-level interventions. Pediatrics. 2020;145(5):e20193832.
15. Aziz S, Khan MA, Qureshi A, et al. Overuse of bronchodilators and corticosteroids in bronchiolitis: a multicentre audit from Pakistan. J Paediatr Infect Dis. 2023;18(2):89-95.
16. Healthcare Quality Improvement Partnership. A Guide to the Clinical Audit Cycle. London: HQIP; 2020.
17. Ogrinc G, Davies L, Goodman D, et al. SQUIRE 2.0 (Standards for Quality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. BMJ Qual Saf. 2016;25(12):986-92.
18. Albrecht S, Babl FE, Dalziel SR, et al. Management of bronchiolitis in Australian hospitals: a retrospective review. J Paediatr Child Health. 2018;54(4):399-404.
19. Bilal H, Khan MN, Rehman T, et al. Antimicrobial resistance patterns of Escherichia coli in Pakistan: a systematic review. J Glob Antimicrob Resist. 2021; 26:269-79.
20. McCulloh RJ, Smitherman SE, Koehn KL, et al. Impact of a bronchiolitis clinical pathway on antibiotic and steroid use. Hosp Pediatr. 2016;6(5):256-64.
21. Mittal V, Darnell C, Walsh B, et al. Inpatient bronchiolitis guideline implementation and resource utilisation. Pediatrics. 2014;133(3):e730-7.
22. Ralston SL, Garber MD, Rice-Conboy E, et al. A multicentre collaborative to reduce unnecessary care in inpatient bronchiolitis. Pediatrics. 2016;137(1):e20150851.
23. Williams DJ, Hall M, Gerber JS, et al. Impact of a national guideline on antibiotic prescribing for bronchiolitis. Pediatrics. 2015;136(4):624-32.

